Author: Dr. David Lowemann

Study Finds Meds May Slow Alzheimer’s in New Way

Two monoclonal antibody treatments to slow Alzheimer’s disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It’s thought the drugs curb Alzheimer’s by reducing levels of toxic amyloid… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder […]

Published on September 12, 2024

High Doses of ADHD Meds Could Trigger Psychosis

Prescriptions for amphetamine stimulants to treat ADHD have increased significantly in recent years, particularly during the pandemic. Unfortunately, high doses of stimulants like Adderall can increase the risk of psychosis or mania by more than fivefold, a new study… Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of […]

Published on September 12, 2024

Light pollution a new Alzheimer’s risk factor

Outdoor light at night could be a significant risk factor in Alzheimer’s disease, according to new research from Rush. Read Full Article (External Site) Dr. David LowemannDr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success […]

Published on September 11, 2024